A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety and efficacy data are a core focus. We seek to reduce development and clinical risks associated with drug development, yet still focus on innovative applications. Our strategy centers on products that have intellectual property and regulatory exclusivity protection, while providing competitive advantages over other existing therapeutic approaches.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 40M | - | - | - | - |
| Net Income | -36M | -34M | -34M | -25M | -18M | -16M |
| EPS | $-2.46 | $-5.57 | $-5.75 | $-5.75 | $-11.25 | $-19.25 |
| Free Cash Flow | 0 | -29M | -28M | -24M | -17M | -12M |
| ROIC | -44.5% | - | -32.7% | -18.5% | -51.9% | -57.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.03 | - | 0.01 | 0.01 | 0.05 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -38M | -37M | -33M | -24M | -18M | -16M |
| Operating Margin | 0.0% | -91.8% | - | - | - | - |
| ROE | -44.9% | - | -32.7% | -18.5% | -52.1% | -57.3% |
| Shares Outstanding | 22M | 159M | 6M | 4M | 6M | 2M |
Citius Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Citius Pharmaceuticals, Inc. (CTXR) has a 5-year average return on invested capital (ROIC) of -40.1%. This is below average and may indicate limited pricing power.
Citius Pharmaceuticals, Inc. (CTXR) has a market capitalization of $18M. It is classified as a small-cap stock.
Citius Pharmaceuticals, Inc. (CTXR) does not currently pay a regular dividend.
Citius Pharmaceuticals, Inc. (CTXR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Citius Pharmaceuticals, Inc. (CTXR) reported annual revenue of $40 million in its most recent fiscal year, based on SEC EDGAR filings.
Citius Pharmaceuticals, Inc. (CTXR) has a net profit margin of -84.2%. The company is currently unprofitable.
Citius Pharmaceuticals, Inc. (CTXR) generated $-29 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Citius Pharmaceuticals, Inc. (CTXR) reported earnings per share (EPS) of $-5.57 in its most recent fiscal year.
The Ledger Terminal provides 13 years of financial data for Citius Pharmaceuticals, Inc. (CTXR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.